{"id":"W2338387150","doi":"10.1200/jco.2009.27.15_suppl.8009","title":"Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Gastroenterology; Cancer; Epidermal growth factor receptor; Sorafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001236123,0.0009299575,0.001601395,0.0003117408,0.0002826284,0.0007518711,0.0006389061,0.0009880315,0.003796075],"category_scores_gemma":[0.0010295,0.0004395171,0.001043686,0.0003205246,0.0007514958,0.0006930237,0.0002774267,0.001773719,0.0006259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006293089,"about_ca_system_score_gemma":0.0009826808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009452479,"about_ca_topic_score_gemma":0.002715262,"domain_scores_codex":[0.999713,0.0001512533,0.00002004091,0.00004138898,0.00002325864,0.00005111012],"domain_scores_gemma":[0.9995013,0.0001471276,0.0001061322,0.00002709235,0.00003182981,0.0001864156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653698,0.006854178,0.001111854,0.0004136358,0.0005838028,0.00004240691,0.00006324452,0.0006047279,0.005027394,0.00009387824,0.0009319027,0.01890315],"study_design_scores_gemma":[0.9259335,0.07027422,0.002003369,0.00001693055,0.0002201365,0.00004198483,0.00001782789,0.0005205328,0.0004257559,0.00008942687,0.0004480949,0.000008323504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936359,0.001945142,0.0003506237,0.0004538949,0.000251947,0.001491012,0.0005467499,0.00006635043,0.001258432],"genre_scores_gemma":[0.9920456,0.001573689,0.0007661303,0.0006062908,0.0002378868,0.001383652,0.0008828615,0.00001716773,0.002486578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003796075,"threshold_uncertainty_score":0.01269913,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04300033028782617,"score_gpt":0.4350229883210954,"score_spread":0.3920226580332692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}